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https://doi.org/10.1016/j.jfma.2017.
0929-6646/Copyright ª 2017, Formosa
BY-NC-ND license (http://creativecomBackground: For advanced rectal cancer with involved or threatened mesorectal fascia (MRF),
current standard is pre-operative long course chemoradiotherapy (PLCRT) with either capeci-
tabine or 5-fluorouracil (5-FU). However, few Chinese data on its clinical outcome are avail-
able, especially for those with pelvic MRI staging.
Methods: Between Jan-2009 and Oct-2014, 123 consecutive patients with biopsy proven
adenocarcinoma of rectum, all with pelvic MRI staging, selected for PLCRT after multi-
disciplinary team discussion were recruited. Their clinical records were retrospectively re-
viewed.
Results: Median follow-up was 1392 days (range: 48e2886) MRI defined poor risk factors as fol-
lows: MRF threatened or involved 1 mm 61.8% (n Z 76), cT4 13.8% (n Z 17), cN2 26.8%
(n Z 33) and low-lying tumor (5 cm from anal verge) 24.4% (n Z 30). Five year OS and
DFS were 63.9% and 68.3% respectively. Among 112 patients who received TME, 108 (96.4%)
had microscopic clear resection (R0). Twelve and 32 individuals had pathological complete
response and ypT0-2N0, respectively. Five local recurrences (4.5%) were detected. The inci-
dence of grade 3 or above acute and late radiotherapy toxicity was 8.1% and 12.2% respec-
tively. After multivariate adjustment, positive circumferential resection margin (CRM) status
on pathology report was found to be significant factor for worse OS and DFS.of Clinical Oncology, The University of Hong Kong, Hong Kong Special Administrative Region. Fax:
C.L. Chiang).
10.002
n Medical Association. Published by Elsevier Taiwan LLC. This is an open access article under the CC
mons.org/licenses/by-nc-nd/4.0/).
826 S.F. Lee et al.Conclusion: The clinical outcomes of PLCRT in our institution are comparable with those in
western literature. Our MRI staging lends support to the validity of data. CRM status is the most
significant prognostic factor in OS and DFS, after multivariate adjustment.
Copyright ª 2017, Formosan Medical Association. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).Introduction
In the last two decades we have witnessed the evolution in
the management of rectal cancer. Though surgery is still the
most important treatment, the management has changed
profoundly and is more relied on the contributions from
other colleagues, like oncologists, radiologists and patholo-
gists. Best clinical management is nowadays increasingly
delivered by an expert multidisciplinary team (MDT).
Surgery is the primary treatment of localized rectal
cancer, but conventional resections had been associated
with local recurrence rate up to 25e40%. Local relapse has
been much reduced after introduction of total mesorectal
excision (TME), which is currently the gold standard pro-
cedure that reduced the rate of local relapse to less than
10% and increased the overall survival.1,2
Multiple randomized studies and meta-analyses have
confirmed adding neo-adjuvant3e8 or adjuvant radio-
therapy1,9e12 will improve the local control rate. Histori-
cally, some argued post-operative radiation is better as
better selection of patients is possible according to the final
pathological stage. However, in the Germany trial (CAO/
ARO/AIO 94)5 that compared the preoperative and post-
operative chemo-irradiation, the preoperative group had a
significant decrease in local failure, acute toxicity, late
toxicity, significant increase in sphincter preservation and
no difference in five year survival. Since then, pre-
operative treatment is preferred in cT3/4 Nþ rectal can-
cer that required combined modality treatment.
For locally advanced rectal cancer (T3/4 or Nþ), there
are two commonly used strategies: pre-operative short
course radiation (PSCRT) (5 Gy per fraction, 5 fractions per
week) followed by immediate surgery that usually carried
out in around 1 week, and pre-op long course chemo-
radiotherapy (PLCRT) (1.8 Gy per fraction, 5 fractions per
week, to a total dose of 45e50 Gy) and surgery was per-
formed after 6e8 weeks of waiting time. Neither approach
is superior in direct comparison, in terms of local control
and overall survival. However, subgroup analyses have
suggested that PSCRT is less effective individuals with
predictive of positive circumferential resection margin
(CRM) or low-lying tumor. In fact PSCRT followed by im-
mediate surgery rarely induced tumor regression. There-
fore, most authorities13e16 have recommended PLCRT,
either concurrent with 5-fluorouracil (5-FU) or capecita-
bine,17 in patients with threatened or involved mesorectal
fascia (MRF), tumor with adjacent organ invasion (cT4
stage) and low-lying tumor. Other high risk factors of local
recurrence would also be taken into consideration, like cN2
disease (four lymph nodes), lateral pelvic lymph node
(internal iliac or obturator lymph nodes) involvement and
extra-mural vascular invasion (EMVI).Magnetic resonance imaging (MRI) now becomes the
impeccable tool for local staging. It defines the location of
tumor and its relationship with MRF and adjacent structure.
Nodal status and EMVI can also be assessed. Multiple studies
have confirmed MRI is highly reliable in predicting
CRM.18e20 On the contrary, multi-slice computed tomogra-
phy (CT) is inferior to MRI in local staging and CRM predic-
tion. Therefore, pre-operative MRI assessment is now the
gold standard in management of rectal cancer. Despite
PLCRT is now the standard treatment of advanced rectal
cancer worldwide, most series reported outcomes based on
rectal cancer variably staged with MRI or CT; few local data
is available, especially for those with MRI staging. There-
fore, we set up a study to report the clinical outcomes of
the 123 Chinese patients with locally advanced rectal
cancer all confirmed with MRI and were treated with PLCRT.
Methods
Patients
For all biopsy proven rectal adenocarcinoma (15 cm from
anal verge) in our hospital, we used high-resolution thin-
slice magnetic resonance imaging (MRI) of pelvis to assess
its local staging; contrast computed tomography (CT) of
thorax, abdomen and pelvis to look for any distant metas-
tasis. All patients had advanced rectal cancer (T3/4 or Nþ)
without distant metastasis (M0) was then referred to MDT
clinic for discussion.
Our institutional protocol defined poor risk factors as
follows: tumor extending to within 1 mm MRF (i.e. antici-
pated CRM threatened or involved); cT3 low lying tumor
(within 5 cm from anal verge); tumor has adjacent organ
involvement (cT4 stage) or cN2 disease (four lymph nodes).
Patients possess one or more risk factors would be treated
with PLCRT. TheMDTassessed all patients’ physical condition
and organ function to confirm their fitness for treatment.
Data were collected retrospectively by performing re-
view of medical records (hard copy and electronic patient
records, pre- and post-treatment radiology, radiotherapy
documentation, surgical notes, pathological reports and
follow-up clinic records). The research ethics committee of
our hospital approved our study.
Treatment
All individuals were scheduled to start chemo-irradiation in
around 2 weeks after MDT clinic. Patients were simulated in
the treatment position (lied prone with a full bladder) using
the belly-board. Target volume was defined using the clin-
ical and radiological information. All patients underwent CT
Table 1 Baseline patient characteristics.
Characteristics Patients (n Z 123)
Age, years
Median (range) 59 (27e79)
Sex, n (%)
Male 95 (77.2)
Female 28 (22.8)
Performance status (ECOG), n (%)
0 14 (11.4)
1 98 (79.7)
2 11 (8.9)
CEA level, n (%)
>5 63 (51.2)
5 60 (48.8)
Distance from anal verge (cm), n (%)
0 to 5 (lower) 34 (27.6)
>5 to 10 (mid) 84 (68.3)
>10 (upper) 5 (4.1)
Clinical T stage, n (%)
T3 106 (86.2)
T4 17 (13.8)
Clinical N stage, n (%)
N0 35 (28.5)
N1 57 (46.3)
N2 31 (25.2)
Mesorectal fascia, n (%)
Involved or threatened (1 mm) 110 (89.4)
>1 mm 13 (10.6)
Neoadjuvant chemoradiation in MRI staged rectal cancer 827planning and the gross tumor volume (GTV) included the
primary tumor and any significant surrounding lymphade-
nopathy. Clinical target volume (CTV) includes GTV plus
2 cm margin and high-risk nodal area includes mesorectal,
pre-sacral, internal iliac and obturator lymph nodes. Plan-
ning target volume defined as CTV þ 1 cm margin to ac-
count for the setup error and organ motion. Patients were
planned using conformal technique in a four to five fields
arrangement to include the PTV within the 95% isodose. A
dose of 45e50.4 Gy in 25e28 fractions over 5e6 week was
prescribed to the 95% isodose line; dose was escalated to
54e56 Gy by means of simultaneous integrated boost (SIB)
in selected bulky T3 and T4 disease.
Concurrent chemotherapy regime, either in form of 5-
fluorouracil (5-FU) intravenous bolus (500 mg/m2 in Day
1e3 and Day 29e31) or capecitabine (825 mg/m2 twice
daily from first day till last day of radiotherapy), was
selected according to patients’ preference. Patients were
monitored weekly for symptoms, performance status, pe-
ripheral blood cell counts, biochemistry and toxicities
during the treatment.
We repeated MRI exam in around 6 weeks after the
completion of chemo-radiation to evaluate treatment
response. Then, we performed TME surgery (either anterior
resection, or abdominoperineal resection at the discretion of
surgeons) at around 8e12 weeks after completion of PLCRT.
MDT clinic will review patients’ recovery and their pa-
thology report within 4 weeks after operation. We started
adjuvant chemotherapy after patients recovered from sur-
gery. Regime of choice includes capecitabine (2500 mg/m2
twice daily for 2 weeks) or CAPOX (oxaliplatin 130 mg/m2 day
1 and capecitabine 2000mg/m2 twice daily for 2weeks), both
repeated every 3 weeks for 6 cycles. Patients’ age, comor-
bidities, performance status, recovery from surgery, and final
pathology stage were taken into consideration. According to
our institutional protocol, combination chemotherapy CAPOX
was offered to patients with ypNþ disease based on the
subgroup analysis result of ADORE trial,21 while capecitabine
or 5-FU alone for patients with ypN0 disease.
Post-treatment follow-up included measurement of
carcinoembryonic antigen (CEA) at every clinic visit. Pa-
tients were reviewed every three months for the two years,
and then every four to six months in the third to fifth years.
We arranged imaging if there was clinical suspicious of
recurrence or increasing trend of CEA. Colonoscopic exam
was performed once within three years and repeated
another within five years. For those with incomplete colo-
noscopy before operation, we carried out first endoscopy
within first year after surgery. Acute and late radiotherapy
side effects were assessed according to according to the
National Cancer Institute Common Terminology Criteria for
Adverse Events version 4.0, and the Toxicity criteria of the
Radiation Therapy Oncology Group and the European Or-
ganization for Research and Treatment of Cancer. Periop-
erative complications represented by rate of 30-day
postoperative mortality and morbidity were also reported.Lateral pelvic lymph nodes, n (%)
Yes 20 (16.3)
No 103 (83.7)
Abbreviations: CEA Z carcinoembryonic antigen; ECOG Z
Eastern Cooperative Oncology Group.Statistical analysis
Data were analyzed using SPSS version 22.0. Survival data
was calculated using the KaplaneMeier method. Overallsurvival (OS) was defined as the time of radiotherapy begins
to death for any reason or the day of last follow-up. Disease
free survival (DFS) was defined as time of commencement
of radiotherapy to date of disease recurrence (distant
metastasis or locoregional recurrence) or death from any
cause, whichever occurred first or the day of last follow-up.
Cox proportional hazards regression model was used to
adjust for various factors.22Results
Between 1st Jan 2009 to 30th Oct 2014, 123 consecutive
rectal cancer patients who had pelvic MRI staging and had
been selected for PLCRT were recruited. Table 1 presents
patients’ baseline characteristics. Median follow-up time
was 1392 days (range: 48e2886). Median age of patients
was 59 years (range from 27 to 79 years). Imaging defined
high risk factors were as follows: total 76 patients (61.8%)
with either threatened or involved MRF (1 mm); 17 pa-
tients (13.8%) were staged as cT4 disease with adjacent
organ(s) invasion; 30 patients (24.4%) had low lying tumor;
and 33 patients (26.8%) had cN2 disease (4 lymph nodes).
All but only two patients completed the planned course
of chemo-radiation. Both of them refused treatment at
828 S.F. Lee et al.27 Gy and 39 Gy due to toxicity respectively. Median time
from the end of chemo-radiotherapy to surgery was 77 days
(interquartile range: 32 days) with 117 individuals proceed
to surgical operation. Total 110 patients with total meso-
rectal excision done (78 anterior resections, 25 abdominal-
perineal resection and nine with other operations). Seven
were found to have inoperable disease at laparotomy.
KaplaneMeier estimates of survival probabilities for pa-
tients who received TME exhibited a better OS and DFS
rates compared with no TME (see Supplementary Fig. 1).
Quality of TME was available in 49 patients, of which 47
(95.9%) had mesorectal fascia plane excision and two (4.1%)
had intramesorectal plane dissection. Among 34 patients
with tumor 5 cm from anal verge, 32 had surgery (two had
inoperable disease at laparotomy). 15 (46.9%) patients had
anterior resection and 17 (53.1%) had abdominal-perineal
resection. But whether sphincter preservation surgery was
performed also depended on age, co-morbidities, tumor
bulkiness and surgical expertise.
The combined incidence of grade 3 or above acute
radiotherapy toxicity to the skin, bowel, and urinary
toxicity was 8.1%. The combined incidence of grade 3 or
above late radiotherapy toxicity to the bowel, and urinary
tract was 12.2%. For grade 3 or above acute chemotherapy-
related toxicity, the incidences of neutropenia, anemia,
and thrombocytopenia were 8.9%, 2.4%, and 0%, respec-
tively. The most common non-hematological grade 3 or
above acute toxicity was diarrhea (5.7%). With regard to
surgical complications, 13 (10.6%) patients had delayed
wound healing, 12 (9.8%) had anastomotic leakages of
different grades, six (4.9%) had post-operative ileus. There
was no 30-day postoperative mortality reported.
Among patients who had TME, 96 (87.3%) received
adjuvant chemotherapy. For 14 (12.7%) patients without
initiation of adjuvant systemic treatment, two due to pa-
tients’ refusal, seven due to poor post-operative recovery
or complications, three were medically unfit, one devel-
oped rapid disease progression, one due to both poor re-
covery and rapid disease progression. 96.4% (106/110) of
the population undergoing TME surgery achieved micro-
scopic clear resection (R0) and 90.6% (106/117) including
for all who underwent operation. Four patients with
involved CRM <1 mm (R1) at pathological specimen.
Among the 110 patients who had TME, 68 patients had
information of their pathological grading of regression,
10.9% (12 out of 110) patients had pathological complete
response (pCR). 25.5% (28 out of 110) had only microscopic
foci, while the remaining 28 (25.5%) reported with no tumor
regression.
The distribution of MRI radiological and pathological
response is highlighted in Table 3. 67.3% (74 out of 110)
patients had T- and/or N-downstaging, and 43.2% (32 out of
74) of them had significant downstaging after PLCRT, with
pathological stage I disease (ypT0-2N0) (see Table 4).
Around 46.4% (51/110) of tumors was over-staged when
comparing post-PLCRT MRI re-staging versus final patho-
logical staging.
33 of 110 patients who had received TME have had
recurrent cancer and 26 have died of recurrence. One pa-
tient died of small cell carcinoma. One patient died of post-
operative complication. Another two individuals died
without proven cancer recurrence (cerebrovascularaccident n Z 1, pneumonia n Z 1); causes of death were
unknown in two patients.
Distant relapse was the commonest mode of failure, it
occurred in 32 patients. Most common site of first recur-
rence was lung metastasis (n Z 20). Other sites of distant
recurrence include liver metastases (n Z 12), peritoneal
disease (n Z 5), para-aortic lymph nodes metastasis
(n Z 8). Multiple sites of relapse were detected in 10 in-
dividuals. Five patients developed local pelvic recurrence,
three patients presented with synchronous distant recur-
rence; one patient had peritoneal disease beforehand and
developed metastasis at the pouch of Douglas; only one
patient had isolated local relapse. Most of the recurrences
were asymptomatic (nZ 25), which was detected by rising
trend of CEA followed by subsequent imaging.
KaplaneMeier curves were performed to evaluate OS
and DFS. Univariate and multivariate analysis using Cox
regression model were used to adjust for different factors
(Table 2). Three year and five year OS were 77.2% and 63.9%
respectively. Three year and five year DFS were 69.4% and
68.3% respectively (Fig. 1). For CRM positive patients, the
OS was significantly compromised and no long term survi-
vor, while for CRM negative patients, three year OS was
88.3% (95% CI 0.80, 0.93). Univariate analyses for OS have
shown that age, Eastern Cooperative Oncology Group
(ECOG) status, time from PLCRT completion to surgery,
histological tumor grading, tumor regression grade, pres-
ence of threatened CRM on final pathology, pathological T
and N stage had p-values  0.100, but after multivariate
adjustment, only threatened CRM (hazard ratio [HR] 18.51,
95% CI 1.29e264.52, p-value Z 0.032) and histological
grade (hazard ratio [HR] 27.72, 95% CI 1.96e392.88, p-
value Z 0.014) remained significant (Fig. 2A). Univariate
analysis revealed that the time from RT completion to
surgery, presence of threatened CRM on final pathology,
pathological T and N stage, and number of histologically
involved lymph node could potentially influence DFS, but
only threatened CRM (HR 8.36, 95% CI 2.31e30.24, p-
value Z 0.001) and pathological N stage (HR 1.83, 95% CI
1.11e3.01, p-value Z 0.018) remained significant after
multivariate adjustment (Fig. 2B).Discussion
pCR rate was 10.9% and five year OS was 63.9%, though
slightly less favorable but still is comparable to local23 and
international data.6,24e26 All of our patients underwent
pelvic MRI as part of their staging investigations, while
other international and local series did not, or only offered
to a portion of patients. Since MRI is standard in deter-
mining locoregional disease status now, we postulated that
our data reflect prognosis more accurately in patients with
T3 with risk factors, T4 and/or N2 disease, treated with
neoadjuvant chemoradiation. Also, our cohort contained
patients with advanced diseases, the inclusion criteria is
also the reason for the different survival figures. Patients
who received TME had better OS and DFS rates. It is likely
that the number of patients who did not receive TME was
too small to draw definitive conclusions from these findings.
Nevertheless, our result showed that the importance of
good TME surgery that is compatible with current evidence.
Table 2 Univariate and multivariate analysisa for OS and DFS.
Factors Univariate
HR
95% CI p-Values Multivariate
HR
95% CI p-Values
For OS
Age (per 1 year increase) 1.04 1.00, 1.07 0.049 1.03 0.95, 1.12 0.495
Sex (female vs. male) 0.92 0.44, 1.94 0.828
ECOG (per 1 score increase) 3.33 1.72, 6.45 <0.001 2.46 0.53, 11.38 0.248
Pretreatment T stage 1.62 0.75, 3.54 0.222
Pretreatment N stage 1.28 0.84, 1.97 0.255
Time from nCRT completion to surgery
(continuous variable)
0.99 0.98, 1.00 0.016 1.00 0.99, 1.01 0.892
MRF involved or threatened (<1 mm) on
baseline MRI staging (yes vs. no)
1.21 0.37, 3.93 0.757
Histological grade (per 1 grade increase) 19.98 2.86, 139.80 0.003 27.72 1.96, 392.88 0.014
Tumor regression gradeb (per 1 grade
increase)
2.52 0.99, 6.45 0.053 0.98 0.27, 3.50 0.971
Presence of threatened CRM on final
pathology (yes vs. no)
21.77 6.51, 72.79 <0.001 18.51 1.29, 264.52 0.032
Pathological T stage 1.37 0.98, 1.93 0.068 1.93 0.34, 10.19 0.440
Pathological N stage 1.63 1.10, 2.44 0.017 2.01 0.55, 7.31 0.288
Number of involved nodesc (continuous
variable)
1.13 1.00, 1.29 0.058
Completion of adjuvant chemotherapy at
full dose (yes vs. no)
0.57 0.20, 1.58 0.280
Pathological response reported (yes vs. no) 0.79 0.36, 3.79 0.765
DFS
Age (per 1 year increase) 0.99 0.95, 1.02 0.420
Sex.(female vs. male) 1.66 0.80, 3.42 0.173
ECOG (per 1 score increase) 1.53 0.70, 3.32 0.286
Pretreatment T stage 2.15 0.93, 4.96 0.073 2.17 0.86, 5.46 0.100
Pretreatment N stage 1.07 0.67, 1.71 0.782
Time from nCRT completion to surgery
(continuous variable)
0.99 0.98, 1.00 0.003 0.99 0.99, 1.00 0.103
MRF involved or threatened (<1 mm) on
baseline MRI staging (yes vs. no)
1.09 0.33, 3.56 0.892
Histological grade (per 1 grade increase) 1.84 0.40, 8.43 0.434
Tumor regression gradeb (per 1 grade
increase)
0.83 0.44, 1.58 0.578
Presence of threatened CRM on final
pathology (yes vs. no)
14.74 4.94, 44.01 <0.001 8.36 2.31, 30.24 0.001
Pathological T stage 1.43 0.97, 2.11 0.072 1.17 0.74, 1.84 0.505
Pathological N stage 2.22 1.47, 3.38 0.001 1.83 1.11, 3.01 0.018
Number of involved nodesc (continuous
variable)
1.18 1.06, 1.32 0.003
Completion of adjuvant chemotherapy at
full dose (yes vs. no)
0.71 0.29, 1.74 0.456
Pathological response reported (yes vs. no) 1.68 0.21, 13.69 0.628
Abbreviations: CRM Z circumferential resection margin; DFS Z disease free survival; ECOG Z Eastern Cooperative Oncology Group;
HR Z hazard ratio; nCRT Z neoadjuvant chemoradiotherapy; OS Z overall survival.
a Factors having p-value  0.100 were selected into the multivariate model.
b Tumor regression grade: 0Z no viable cancer cell; 1Z single cells or small groups of cancer cells; 2Z residual cancer outgrown by
fibrosis; 3 Z minimal or no tumor kill and extensive residual cancer.
c Number of involved nodes was not included in multivariate analysis of DFS to avoid collinearity with pathological N stage.
Neoadjuvant chemoradiation in MRI staged rectal cancer 829Together with the downstaging effects, the completion
resection rate was high (96.4%), which is most important for
cure in rectal cancer. CRM status is prognostic factors for OS
and DFS, it remains significant after multivariate adjust-
ment. Studies have shown CRM involvement is anindependent prognostic factor, it not only predicts local
recurrence, but also distant metastasis and overall sur-
vival.27 In our cohort, local recurrence was low in both
groups, however, patients with CRM involvement were
more commonly associated with distant metastases and
Table 3 Responses after PLCRT.
MRI radiological responses
Responses n Proportions (n Z 123)
CR 0 0%
PR 63 51.2%
Stable 56 45.5%
PD 4 3.3%
Objective response rate 63 51.2%
Pathological responses
Baseline MRI clinical staging Pathological T staging Pathological
node negative
Pathological
node positiveypT0 ypT1 ypT2 ypT3 ypT4
cT3 13 4 15 66 1 e e
cT4 2 0 0 7 5 e e
Node negative e e e e e 24 8
Node positive e e e e e 54 26
Table 4 Pathological downstaging after PLCRT.
Pathological downstaging n Proportion
(total Z 110)
T-downstaging only 17 15.5%
N-downstaging only 34 30.9%
Both T- and Ndownstaging 23 20.9%
Significant downstaging (ypT0-2N0) 32 29.1%
830 S.F. Lee et al.that is accounted for poorer DFS & OS. It is in line with the
current literature. We could not find association between
time from chemoradiation completion to surgery and
outcome, likely due to the sample size.
The benefit of adjuvant chemotherapy in rectal cancer
is controversial, especially after PLCRT and definitiveFig. 1 KaplaneMeier curves. KaplaneMeier estimate for (A) OS a
survival; DFS Z disease free survival.rectal operation. The long term result from EORTC 2292128
showed that adjuvant chemotherapy with 5-fluorouracil
(5-FU) and folinic acid after preoperative radiotherapy
(with or without chemotherapy) did not affect DFS or OS in
cT3-4 resectable rectal cancer. Similar findings were
detected in other trials, using 5-FU based29 or oxaliplatin
based adjuvant chemotherapy.30 However, studies have
shown that adding oxaliplatin to adjuvant21 and/or neo-
adjuvant31 treatment can improve DFS. In our study,
completion of adjuvant chemotherapy at full dose was not
a prognostic factor. This highlights the importance of
future research, preferably in prospective manner, to
assess the benefit of adjuvant chemotherapy in this
context.
Pelvic MRI is standard staging modality in rectal cancer.
In our series, all our patients underwent MRI as part ofnd (B) DFS of the whole study cohort (n Z 123). OS Z overall
Fig. 2 KaplaneMeier curves according to CRM status. KaplaneMeier estimate for (A) OS and (B) DFS (n Z 123).
CRM Z circumferential resection margin; OS Z overall survival; DFS Z disease free survival.
Neoadjuvant chemoradiation in MRI staged rectal cancer 831initial staging, this ensured the accuracy of our staging.
However, it was not uncommon we encountered the prob-
lem of over-staging in the post-PLCRT MRI. There are re-
ports suggesting that post-PLCRT MRI is often unable to
differentiate between viable tumor, residual fibrotic non-
tumor tissue, and desmoplastic reaction, resulting in poor
agreement between post-PLCRT MRI and pathologic staging
in both T and N stages.32 In our data, a significant portion of
patients were over-staged by post-PLCRT MRI re-staging. On
the other hand 67.3% patients responded to PLCRT by
RECIST criteria (T-downstaging, N-downstaging and T-/N-
downstaging). These figures are compatible with modern
series. However, our follow up time was long, we could
reliably report late toxicity. Our study had certain limita-
tions. Our data were collected retrospectively, there could
be selective bias and other unknown confounding factors.
Toxicity data and comorbidities were not systematically
recorded, this may lead to inadequate statistical adjust-
ment. Our sample size limited the ability to adjust for po-
tential confounding factors and long term toxicity requires
longer follow up to conclude.
Conclusion
The clinical outcomes of PLCRT in our institution are com-
parable with those in western literature. Our MRI staging
lends support to the validity of data. CRM status is the most
significant prognostic factor in OS and DFS, after multivar-
iate adjustment.
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